Table 1 The clinical data including age, sex, exposure history and laboratory parameters of all the collected patients

Gender

0.329

0.566

 Male

37 (50.7)

14 (46.7)

23 (53.5)

 Female

36 (49.3)

16 (53.3)

20 (46.5)

Age(y)

41 (33–55.5)

54 (36–64)

37 (32–47)

3.091

0.002*

Exposure History

34.717

< 0.001*

 Wuhan contact

29 (39.7)

24 (80.0)

5 (11.6)

 Hubei (not Wuhan) contact

10 (13.7)

2 (6.7)

8 (18.6)

 Not Hubei contact or Cluster onset

34 (46.6)

4 (13.3)

30 (69.8)

Duration between CT and symptom onset (day)

3 (1–6)

3 (1–5.25)

3 (1–7)

−0.074

0.941

 Fever

45 (61.6)

22 (73.3)

23 (53.5)

2.943

0.086

 Cough

49 (67.1)

17 (56.7)

32 (74.4)

2.523

0.112

 Sputum production

19 (26.0)

5 (16.7)

14 (32.6)

2.318

0.128

 Running/stuffy nose

3 (4.1)

0 (0.0)

3 (7.0)

2.183

0.264

 Fatigue

8 (11.0)

2 (6.7)

6 (14.0)

1.016

0.314

 Muscle ache/myalgia

15 (20.5)

7 (23.3)

8 (18.6)

0.242

0.623

 Diarrhea

4 (5.5)

4 (13.3)

0 (0.0)

7.450

0.006*

 Chest pain

1 (1.4)

0 (0.0)

1 (2.3)

1.068

0.301

 Sore throat

10 (13.7)

2 (6.7)

8 (18.6)

2.307

0.129

 Headache

8 (11.0)

3 (10.0)

5 (11.6)

0.048

0.826

 White-cell count(10⁻⁹ g/L)

(normal range 3.89–9.93)

6.81 (5.40–8.37)

5.43 (4.25–6.12)

7.67 (6.73–9.06)

−4.547

< 0.001*

 Neutrophil percentage(%)

(normal range 44.0–72.0)

64.45 (57.70–73.45)

64.80 (61.35–73.38)

64.45 (55.38–73.70)

0.908

0.364

 Neutrophil count(10⁻⁹ g/L)

(normal range 2.01–7.42)

4.21 (3.30–5.96)

3.46 (3.00–4.32)

4.92 (3.75–7.09)

−3.295

0.001*

Lymphocyte percentage(%)

(normal range 20.0–45.0)

26.15 (18.05–31.08)

25.25 (17.58–31.03)

26.75 (18.55–32.55)

−0.423

0.673

 Lymphocyte count(10⁻⁹ g/L)

(normal range 1.06–3.61)

1.70 (1.28–2.36)

1.32 (1.08–1.69)

1.93 (1.54–2.64)

−3.667

< 0.001*

 Influenza

2

–

2

 Mycoplasma pneumonia

7

–

7

 Pneumocystis carinii pneumonia

1

–

1

 Community-acquired pneumonia of unknown cause

33

–

33